$NTRB
NutriBand Inc. Stock $ntrb

$ntrb Overview Financials Valuation SEC Filings Company Website

2023 Q2 Form 10-K Financial Statement

#000121390023032682 Filed on April 26, 2023

Income Statement

Concept	2023 Q2	2023 Q1	2023
Revenue	$476.9K	$527.5K	$2.080M
YoY Change	-0.21%	7.25%	46.23%
Cost Of Revenue	$254.6K	$398.1K	$1.329M
YoY Change	-8.22%	2.47%	44.82%
Gross Profit	$222.3K	$129.4K	$750.4K
YoY Change	10.88%	25.21%	48.8%
Gross Profit Margin	46.61%	24.53%	36.08%
Selling, General & Admin	$839.7K	$1.190M	$3.916M
YoY Change	9.26%	-17.79%	-2.65%
% of Gross Profit	377.77%	919.47%	521.86%
Research & Development	$400.4K	$295.8K	$982.2K
YoY Change	239.89%	18.15%	138.76%
% of Gross Profit	180.14%	228.62%	130.89%
Depreciation & Amortization	$75.20K	$74.21K	$330.1K
YoY Change	-2.94%	-51.47%	6.93%
% of Gross Profit	33.83%	57.35%	44.0%
Operating Expenses	$1.240M	$1.486M	$4.898M
YoY Change	39.92%	-12.49%	10.47%
Operating Profit	-$1.018M	-$1.356M	-$4.475M
YoY Change	48.4%	-14.93%	13.88%
Interest Expense	$2.650K	$4.220K	-$8.290K
YoY Change	-164.48%	-233.97%	-93.0%
% of Operating Profit
Other Income/Expense, Net	$2.649K		$5.226M
YoY Change	-164.45%		-21.0%
Pretax Income	-$1.015M	-$1.679M	-$4.483M
YoY Change	47.14%	-55.44%	-27.41%
Income Tax		$0.00
% Of Pretax Income
Net Earnings	-$1.015M	-$1.679M	-$4.483M
YoY Change	47.14%	-55.44%	-27.41%
Net Earnings / Revenue	-212.87%	-318.33%	-215.59%
Basic Earnings Per Share	-$0.13		-$0.53
Diluted Earnings Per Share	-$0.13	-$0.21	-$0.53
COMMON SHARES
Basic Shares Outstanding	7.833M shares		8.460M shares
Diluted Shares Outstanding	7.833M shares		8.460M shares

Balance Sheet

Concept	2023 Q2	2023 Q1	2023
SHORT-TERM ASSETS
Cash & Short-Term Investments	$1.278M	$1.985M	$1.985M
YoY Change	-68.13%	-59.41%	-59.41%
Cash & Equivalents	$1.278M	$1.985M	$1.985M
Short-Term Investments
Other Short-Term Assets	$369.3K	$365.9K	$365.9K
YoY Change	-8.74%	-1.23%	-1.23%
Inventory	$181.5K	$229.3K	$229.3K
Prepaid Expenses	$369.3K	$365.9K
Receivables	$164.6K	$113.0K	$113.1K
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$1.993M	$2.694M	$2.694M
YoY Change	-57.05%	-50.71%	-50.71%
LONG-TERM ASSETS
Property, Plant & Equipment	$853.4K	$897.7K	$960.5K
YoY Change	-22.35%	-10.08%	-3.79%
Goodwill	$5.022M	$5.022M
YoY Change		-6.12%
Intangibles	$752.1K	$780.4K
YoY Change		-15.8%
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets	$6.682M	$6.763M	$6.763M
YoY Change	-8.99%	-7.03%	-7.03%
TOTAL ASSETS
Total Short-Term Assets	$1.993M	$2.694M	$2.694M
Total Long-Term Assets	$6.682M	$6.763M	$6.763M
Total Assets	$8.676M	$9.456M	$9.456M
YoY Change	-27.61%	-25.77%	-25.77%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$543.8K	$534.7K	$534.7K
YoY Change	1.55%	-16.4%	-16.4%
Accrued Expenses	$32.01K	$31.29K	$31.29K
YoY Change	-5.55%	61.87%	61.87%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$19.93K	$19.74K	$19.74K
YoY Change	-16.08%	39.8%	39.8%
Total Short-Term Liabilities	$784.4K	$748.6K	$748.6K
YoY Change	8.48%	-3.93%	-3.93%
LONG-TERM LIABILITIES
Long-Term Debt	$145.4K	$100.5K	$100.5K
YoY Change	25.64%	-0.61%	-0.61%
Other Long-Term Liabilities	$26.00K	$34.28K	$34.28K
YoY Change	-60.35%
Total Long-Term Liabilities	$171.4K	$134.8K	$134.8K
YoY Change	-5.45%	33.29%	33.29%
TOTAL LIABILITIES
Total Short-Term Liabilities	$784.4K	$748.6K	$748.6K
Total Long-Term Liabilities	$171.4K	$134.8K	$134.8K
Total Liabilities	$955.8K	$883.4K	$883.4K
YoY Change	5.69%	0.34%	0.34%
SHAREHOLDERS EQUITY
Retained Earnings	-$23.51M	-$22.49M
YoY Change		24.89%
Common Stock	$7.833K	$7.833K
YoY Change		-14.44%
Preferred Stock
YoY Change
Treasury Stock (at cost)	$32.64K	$32.64K
YoY Change		-68.75%
Treasury Stock Shares
Shareholders Equity	$7.720M	$8.573M	$8.573M
YoY Change
Total Liabilities & Shareholders Equity	$8.676M	$9.456M	$9.456M
YoY Change	-27.61%	-25.77%	-25.77%

Cashflow Statement

Concept	2023 Q2	2023 Q1	2023
OPERATING ACTIVITIES
Net Income	-$1.015M	-$1.679M	-$4.483M
YoY Change	47.14%	-55.44%	-27.41%
Depreciation, Depletion And Amortization	$75.20K	$74.21K	$330.1K
YoY Change	-2.94%	-51.47%	6.93%
Cash From Operating Activities	-$749.9K	-$814.0K	-$2.987M
YoY Change	0.75%	-66.66%	6.34%
INVESTING ACTIVITIES
Capital Expenditures	$2.624K	$10.02K	$79.30K
YoY Change	-105.99%	-131.12%	-197.19%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities	-$2.624K	-$10.02K	-$79.30K
YoY Change	-94.01%	-68.88%	-2.81%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net			$0.00
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	$45.12K	-6.850K	$160.1K
YoY Change	-148.44%	-100.1%	-97.9%
NET CHANGE
Cash From Operating Activities	-$749.9K	-814.0K	-$2.987M
Cash From Investing Activities	-$2.624K	-10.02K	-$79.30K
Cash From Financing Activities	$45.12K	-6.850K	$160.1K
Net Change In Cash	-$707.4K	-830.9K	-$2.906M
YoY Change	-19.73%	-118.11%	-161.32%
FREE CASH FLOW
Cash From Operating Activities	-$749.9K	-$814.0K	-$2.987M
Capital Expenditures	$2.624K	$10.02K	$79.30K
Free Cash Flow	-$752.5K	-$824.0K	-$3.067M
YoY Change	7.43%	-65.79%	12.42%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit		usd
CY2022	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit		usd
CY2023	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit		usd
CY2022	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit		usd
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
CY2023Q1	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet		usd
CY2022Q1	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet		usd
CY2023	dei	Document Type DocumentType	10-K
CY2023	dei	Document Annual Report DocumentAnnualReport	true
CY2023	dei	Document Period End Date DocumentPeriodEndDate	2023-01-31
CY2023	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--01-31
CY2023	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2023	dei	Document Transition Report DocumentTransitionReport	false
CY2023	dei	Entity File Number EntityFileNumber	000-55654
CY2023	dei	Entity Registrant Name EntityRegistrantName	NUTRIBAND INC.
CY2023	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	NV
CY2023	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	81-1118176
CY2023	dei	Entity Address Address Line1 EntityAddressAddressLine1	121 South Orange Ave
CY2023	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 1500
CY2023	dei	Entity Address City Or Town EntityAddressCityOrTown	Orlando
CY2023	dei	Entity Address State Or Province EntityAddressStateOrProvince	FL
CY2023	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	32801
CY2023	dei	City Area Code CityAreaCode	(407)
CY2023	dei	Local Phone Number LocalPhoneNumber	377-6695
CY2023	dei	Security12b Title Security12bTitle	Common Stock
CY2023	dei	Trading Symbol TradingSymbol	NTRB
CY2023	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2023	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2023	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023	dei	Document Fin Stmt Error Correction Flag DocumentFinStmtErrorCorrectionFlag	false
CY2023	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2023	dei	Entity Small Business EntitySmallBusiness	true
CY2023	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
CY2023	dei	Entity Ex Transition Period EntityExTransitionPeriod	true
CY2023	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	false
CY2023	dei	Entity Shell Company EntityShellCompany	false
CY2022Q3	dei	Entity Public Float EntityPublicFloat	21711078	usd
CY2023Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	7833150	shares
CY2023	dei	Auditor Firm AuditorFirmId	3627
CY2023	dei	Auditor Name AuditorName	Sadler, Gibb & Associates, LLC
CY2023	dei	Auditor Location AuditorLocation	Draper, UT
CY2023Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	1985440	usd
CY2022Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	4891868	usd
CY2023Q1	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	113045	usd
CY2022Q1	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	71380	usd
CY2023Q1	us-gaap	Inventory Net InventoryNet	229335	usd
CY2022Q1	us-gaap	Inventory Net InventoryNet	131648	usd
CY2023Q1	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	365925	usd
CY2022Q1	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	370472	usd
CY2023Q1	us-gaap	Assets Current AssetsCurrent	2693745	usd
CY2022Q1	us-gaap	Assets Current AssetsCurrent	5465368	usd
CY2023Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	897735	usd
CY2022Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	979297	usd
CY2023Q1	us-gaap	Goodwill Goodwill	5021713	usd
CY2022Q1	us-gaap	Goodwill Goodwill	5349039	usd
CY2023Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	62754	usd
CY2022Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	19043	usd
CY2023Q1	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	780430	usd
CY2022Q1	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	926913	usd
CY2023Q1	us-gaap	Assets Assets	9456377	usd
CY2022Q1	us-gaap	Assets Assets	12739660	usd
CY2023Q1	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	534679	usd
CY2022Q1	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	639539	usd
CY2023Q1	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	162903	usd
CY2022Q1	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	106267	usd
CY2023Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	31291	usd
CY2022Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	19331	usd
CY2023Q1	us-gaap	Notes Payable Current NotesPayableCurrent	19740	usd
CY2022Q1	us-gaap	Notes Payable Current NotesPayableCurrent	14119	usd
CY2023Q1	us-gaap	Liabilities Current LiabilitiesCurrent	748613	usd
CY2022Q1	us-gaap	Liabilities Current LiabilitiesCurrent	779256	usd
CY2023Q1	us-gaap	Long Term Notes Payable LongTermNotesPayable	100497	usd
CY2022Q1	us-gaap	Long Term Notes Payable LongTermNotesPayable	101119	usd
CY2023Q1	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	34277	usd
CY2023Q1	us-gaap	Liabilities Liabilities	883387	usd
CY2022Q1	us-gaap	Liabilities Liabilities	880375	usd
CY2023Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2022Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2023Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2022Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2023Q1	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2022Q1	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2023Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2023Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	291666666	shares
CY2022Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	291666666	shares
CY2023Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	7843150	shares
CY2022Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	9187659	shares
CY2023Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	7833150	shares
CY2022Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	9154846	shares
CY2023Q1	us-gaap	Common Stock Value CommonStockValue	7833	usd
CY2022Q1	us-gaap	Common Stock Value CommonStockValue	9155	usd
CY2023Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	31092807	usd
CY2022Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	29966132	usd
CY2023Q1	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-304	usd
CY2022Q1	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-304	usd
CY2023Q1	us-gaap	Treasury Stock Common Shares TreasuryStockCommonShares	10000	shares
CY2022Q1	us-gaap	Treasury Stock Common Shares TreasuryStockCommonShares	32813	shares
CY2023Q1	us-gaap	Treasury Stock Value TreasuryStockValue	32641	usd
CY2022Q1	us-gaap	Treasury Stock Value TreasuryStockValue	104467	usd
CY2023Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-22494705	usd
CY2022Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-18011231	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	8572990	usd
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	11859285	usd
CY2023Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	9456377	usd
CY2022Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	12739660	usd
CY2023	us-gaap	Revenues Revenues	2079609	usd
CY2022	us-gaap	Revenues Revenues	1422154	usd
CY2023	us-gaap	Cost Of Revenue CostOfRevenue	1329200	usd
CY2022	us-gaap	Cost Of Revenue CostOfRevenue	917844	usd
CY2023	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	982227	usd
CY2022	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	411383	usd
CY2023	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	327326	usd
CY2022	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	2180836	usd
CY2023	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	3916041	usd
CY2022	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	4022824	usd
CY2023	us-gaap	Costs And Expenses CostsAndExpenses	6554794	usd
CY2022	us-gaap	Costs And Expenses CostsAndExpenses	7532887	usd
CY2023	us-gaap	Operating Income Loss OperatingIncomeLoss	-4475185	usd
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-6110733	usd
CY2022	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	53028	usd
CY2023	us-gaap	Interest Expense Debt InterestExpenseDebt	8289	usd
CY2022	us-gaap	Interest Expense Debt InterestExpenseDebt	118421	usd
CY2023	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-8289	usd
CY2022	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-65393	usd
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-4483474	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-6176126	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-4483474	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-6176126	usd
CY2022	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	-196589	usd
CY2023	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-4483474	usd
CY2022	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-6372715	usd
CY2023	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.53
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.8
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	8459547	shares
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	7932895	shares
CY2023	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-4483474	usd
CY2022	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-6372715	usd
CY2023	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	-4483474	usd
CY2022	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	-6372715	usd
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	11859285	usd
CY2023	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	296875	usd
CY2023	us-gaap	Stock Issued During Period Value Treasury Stock Reissued StockIssuedDuringPeriodValueTreasuryStockReissued	113155	usd
CY2023	us-gaap	Stock Issued During Period Value Stock Dividend StockIssuedDuringPeriodValueStockDividend	174025	usd
CY2023	us-gaap	Stock Repurchased And Retired During Period Value StockRepurchasedAndRetiredDuringPeriodValue	-119006	usd
CY2023	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	732130	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-4483474	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	8572990	usd
CY2021Q1	us-gaap	Stockholders Equity StockholdersEquity	7111946	usd
CY2022	ntrb	Proceeds From Sale Of Common Stock And Warrants In Public Offering ProceedsFromSaleOfCommonStockAndWarrantsInPublicOffering	5836230	usd
CY2022	ntrb	Stock Issued During Period Proceeds From Exercise Of Warrants StockIssuedDuringPeriodProceedsFromExerciseOfWarrants	2942970	usd
CY2022	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	100000	usd
CY2022	ntrb	Stock Issued During Period Common Stock Issued For Settlement Of Liabilities StockIssuedDuringPeriodCommonStockIssuedForSettlementOfLiabilities	144000	usd
CY2022	us-gaap	Adjustment Of Warrants Granted For Services AdjustmentOfWarrantsGrantedForServices	365000	usd
CY2022	ntrb	Common Stock Issued For Proceeds And In Payment For License CommonStockIssuedForProceedsAndInPaymentForLicense	640000	usd
CY2022	ntrb	Common Stock Issued For Settlement Of Liabilities CommonStockIssuedForSettlementOfLiabilities	466900	usd
CY2022	us-gaap	Stock Repurchased And Retired During Period Value StockRepurchasedAndRetiredDuringPeriodValue	-104467	usd
CY2022	us-gaap	Stock Issued During Period Value Employee Stock Ownership Plan StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan	532832	usd
CY2022	ntrb	Settlement Of Warrant Round Down SettlementOfWarrantRoundDown	-196589	usd
CY2022	ntrb	Stock Issued During Period Demmed Dividend From Warrants StockIssuedDuringPeriodDemmedDividendFromWarrants	196589	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-6176126	usd
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	11859285	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-4483474	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-6176126	usd
CY2023	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	330143	usd
CY2022	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	308741	usd
CY2022	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	97477	usd
CY2023	us-gaap	Amortization Of Leased Asset AmortizationOfLeasedAsset	38813	usd
CY2022	us-gaap	Amortization Of Leased Asset AmortizationOfLeasedAsset	9522	usd
CY2022	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	53028	usd
CY2023	ntrb	Stockbased Compensationoptions StockbasedCompensationoptions	732130	usd
CY2022	ntrb	Stockbased Compensationoptions StockbasedCompensationoptions	532832	usd
CY2023	ntrb	Stockbased Compensationwarrants StockbasedCompensationwarrants	0	usd
CY2022	ntrb	Stockbased Compensationwarrants StockbasedCompensationwarrants	365000	usd
CY2023	ntrb	Treasury Stock Issued For Termination Agreement TreasuryStockIssuedForTerminationAgreement	174025	usd
CY2023	ntrb	Treasury Stock Issued For Services TreasuryStockIssuedForServices	113155	usd
CY2023	us-gaap	Goodwill And Intangible Asset Impairment GoodwillAndIntangibleAssetImpairment	327326	usd
CY2022	us-gaap	Goodwill And Intangible Asset Impairment GoodwillAndIntangibleAssetImpairment	2180836	usd
CY2022	ntrb	Common Stock Issued For Service CommonStockIssuedForService	466900	usd
CY2023	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	41665	usd
CY2022	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-42967	usd
CY2023	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	-4547	usd
CY2022	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	370472	usd
CY2023	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	97687	usd
CY2022	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	78800	usd
CY2023	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	56636	usd
CY2022	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	19421	usd
CY2023	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-36287	usd
CY2022	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-9234	usd
CY2023	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-104860	usd
CY2022	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-145259	usd
CY2023	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-2987198	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-2809223	usd
CY2023	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	79304	usd
CY2022	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	81595	usd
CY2023	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-79304	usd
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-81595	usd
CY2022	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	583000	usd
CY2022	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	5836230	usd
CY2023	us-gaap	Proceeds From Issuance Of Warrants ProceedsFromIssuanceOfWarrants	296875	usd
CY2022	us-gaap	Proceeds From Issuance Of Warrants ProceedsFromIssuanceOfWarrants	2942970	usd
CY2023	ntrb	Payment On Note Payable PaymentOnNotePayable	17795	usd
CY2022	ntrb	Payment On Note Payable PaymentOnNotePayable	5496	usd
CY2022	us-gaap	Repayments Of Related Party Debt RepaymentsOfRelatedPartyDebt	1500000	usd
CY2022	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	121544	usd
CY2023	ntrb	Purchase Of Treasury Stock PurchaseOfTreasuryStock	-119006	usd
CY2022	ntrb	Purchase Of Treasury Stock PurchaseOfTreasuryStock	-104467	usd
CY2023	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	160074	usd
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	7630693	usd
CY2023	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-2906428	usd
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	4739875	usd
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	4891868	usd
CY2021Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	151993	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	1985440	usd
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	4891868	usd
CY2023	us-gaap	Interest Paid Net InterestPaidNet	4266	usd
CY2022	us-gaap	Interest Paid Net InterestPaidNet	18598	usd
CY2023	ntrb	Common Stock Returned In Settlement CommonStockReturnedInSettlement	1400	usd
CY2022	ntrb	Common Stock Issued For Settlement Of Notes Payable CommonStockIssuedForSettlementOfNotesPayable	100000	usd
CY2022	ntrb	Common Stock Issued For Prepaid Consulting CommonStockIssuedForPrepaidConsulting	400000	usd
CY2022	ntrb	Noncash Payment For License Agreement NoncashPaymentForLicenseAgreement	57000	usd
CY2022	ntrb	Common Stock Issued For Subscription Payable CommonStockIssuedForSubscriptionPayable	70000	usd
CY2023	ntrb	Adoption Of Operating Lease Asset And Liability AdoptionOfOperatingLeaseAssetAndLiability	94134	usd
CY2022	ntrb	Adoption Of Operating Lease Asset And Liability AdoptionOfOperatingLeaseAssetAndLiability	28565	usd
CY2023	ntrb	Promissory Note On Equipment Purchase PromissoryNoteOnEquipmentPurchase	22794	usd
CY2022	ntrb	Settlement Of Liabilities For Common Stock SettlementOfLiabilitiesForCommonStock	144000	usd
CY2022	ntrb	Deemed Dividend In Connection With Warrant Round Down DeemedDividendInConnectionWithWarrantRoundDown	196589	usd
CY2022	us-gaap	Noncash Or Part Noncash Acquisition Net Nonmonetary Assets Acquired Liabilities Assumed1 NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1	15	usd
CY2018Q3	ntrb	Description Of Acquired DescriptionOfAcquired	On August 1, 2018, the Company acquired 4P Therapeutics LLC (“4P Therapeutics”) for $2,250,000, consisting of 250,000 shares of common stock, valued at $1,850,000, and $400,000, and a royalty of 6% on all revenue generated by the Company from the abuse deterrent intellectual property that had been developed by 4P Therapeutics payable to the former owner of 4P Therapeutics. The former owner of 4P Therapeutics has been a director of the Company since April 2018, when the Company entered into an agreement to acquire 4P Therapeutics.
CY2020Q3	ntrb	Acquired Percentage AcquiredPercentage	1	pure
CY2022Q3	us-gaap	Stockholders Equity Note Stock Split StockholdersEquityNoteStockSplit	The 7:6 forward stock split was effective for trading purposes on the Nasdaq Capital Market on August 12, 2022.
CY2023Q1	us-gaap	Other Cash Equivalents At Carrying Value OtherCashEquivalentsAtCarryingValue	1985440	usd
CY2023	ntrb	Working Capital WorkingCapital	1945132	usd
CY2023	ntrb	Operation Income OperationIncome	4483474	usd
CY2023	ntrb	Cash Flow From Operations CashFlowFromOperations	2987198	usd
CY2021Q4	ntrb	Proceeds From Issuances Initial Public Offering ProceedsFromIssuancesInitialPublicOffering	5836230	usd
CY2023	ntrb	Proceeds From Warrants Exercises ProceedsFromWarrantsExercises	3239845	usd
CY2023	us-gaap	Use Of Estimates UseOfEstimates	<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; background-color: white"><i><span style="text-decoration:underline">Use of Estimates </span></i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; background-color: white"><i> </i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; background-color: white">The preparation of the consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires the Company to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosure of contingent assets and liabilities. On an ongoing basis, the Company evaluates its estimates including, but not limited to, those related to such items as income tax exposures, accruals, depreciable/useful lives, allowance for doubtful accounts and valuation allowances. The Company bases its estimates on historical experience and on other various assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results could differ from those estimates.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; background-color: white"> </p>
CY2023	us-gaap	Revenue Recognition Deferred Revenue RevenueRecognitionDeferredRevenue	<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 2.25pt"><i><span style="text-decoration:underline">Contract Liabilities</span></i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 2.25pt"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Deferred revenue is a liability related to a revenue producing activity for which revenue has not been recognized. The Company records deferred revenue when it receives consideration from a contract before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; background-color: white"><i> </i></p>
CY2022Q3	ntrb	Stockholder Equity Note Stock Split StockholderEquityNoteStockSplit	the Company effected a 7-for-6 forward stock split pursuant to which each shareholder of record as of the August 12, 2022, record date received one (1) additional share for each six (6) shares held as of the record date.
CY2023	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	1785507	usd
CY2022	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	1179620	usd
CY2023	us-gaap	Cost Of Services Catering CostOfServicesCatering	294102	usd
CY2022	us-gaap	Cost Of Services Catering CostOfServicesCatering	242534	usd
CY2023	ntrb	Total Revenue TotalRevenue	2079609	usd
CY2022	ntrb	Total Revenue TotalRevenue	1422154	usd
CY2023	ntrb	Total Revenue TotalRevenue	2079609	usd
CY2022	ntrb	Total Revenue TotalRevenue	1422154	usd
CY2022Q2	us-gaap	Sale Of Stock Number Of Shares Issued In Transaction SaleOfStockNumberOfSharesIssuedInTransaction	35584	shares
CY2022Q2	ntrb	Treasury Stock Purchase TreasuryStockPurchase	119006	usd
CY2023Q1	us-gaap	Other Inventory OtherInventory	29335	usd
CY2023Q1	us-gaap	Inventory Work In Process InventoryWorkInProcess	11021	usd
CY2023Q1	us-gaap	Inventory Raw Materials InventoryRawMaterials	218334	usd
CY2023Q1	us-gaap	Derivative Fixed Interest Rate DerivativeFixedInterestRate	1	pure
CY2022Q1	us-gaap	Derivative Fixed Interest Rate DerivativeFixedInterestRate	1	pure
CY2023	ntrb	Estimated Useful Live EstimatedUsefulLive	P10Y
CY2023	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	941530	usd
CY2022	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	1296987	usd
CY2023	us-gaap	Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost	168768	usd
CY2023Q1	ntrb	Goodwill Value GoodwillValue	1719235	usd
CY2020Q3	ntrb	Goodwill Value GoodwillValue	5810640	usd
CY2023Q1	us-gaap	Goodwill Impaired Accumulated Impairment Loss GoodwillImpairedAccumulatedImpairmentLoss	3302478	usd
CY2023	us-gaap	Goodwill Other Increase Decrease GoodwillOtherIncreaseDecrease	5021713	usd
CY2022	us-gaap	Goodwill Other Increase Decrease GoodwillOtherIncreaseDecrease	5349039	usd
CY2023Q1	us-gaap	Common Stock Other Shares Outstanding CommonStockOtherSharesOutstanding	1778006	shares
CY2022Q1	us-gaap	Common Stock Other Shares Outstanding CommonStockOtherSharesOutstanding	1503171	shares
CY2022	us-gaap	Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost	286594	usd
CY2023	us-gaap	Income Tax Reconciliation Nondeductible Expense Impairment Losses IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses	68738	usd
CY2022	us-gaap	Income Tax Reconciliation Nondeductible Expense Impairment Losses IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses	457976	usd
CY2023	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; background-color: white"><i><span style="text-decoration:underline">Concentration of Credit Risk</span></i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; background-color: white"><i> </i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; background-color: white">Financial instruments which potentially subject the Company to concentrations of credit risk consist principally of cash. The Company’s cash and cash equivalents are concentrated primarily in banks. At times, such deposits could be in excess of insured limits. Management believes that the financial institutions that hold the Company’s financial instruments are financially sound and, accordingly, minimal credit risk is believed to exist with respect to those financial interests. As of and for the year ended January 31, 2023, two customers accounted for 34% and 14% of the Company’s revenue and one customer accounted for 94% of accounts receivable. As of and for the year ended January 31, 2022, three customers accounted for 19%, 17% and 13% of the Company’s revenue and three customers accounted for 58%, 21% and 17% of accounts receivable.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; background-color: white"> </p>
CY2023	ntrb	Accounts Receivable AccountsReceivable	0.94	pure
CY2023	us-gaap	Income Tax Reconciliation Nondeductible Expense Other IncomeTaxReconciliationNondeductibleExpenseOther	704024	usd
CY2022	us-gaap	Income Tax Reconciliation Nondeductible Expense Other IncomeTaxReconciliationNondeductibleExpenseOther	552417	usd
CY2023Q1	us-gaap	Operating Loss Carryforwards Valuation Allowance OperatingLossCarryforwardsValuationAllowance	11000000	usd
CY2023Q1	us-gaap	Property Plant And Equipment Other PropertyPlantAndEquipmentOther	1404856	usd
CY2022Q1	us-gaap	Property Plant And Equipment Other PropertyPlantAndEquipmentOther	1302758	usd
CY2023Q1	us-gaap	Property Plant And Equipment Other Accumulated Depreciation PropertyPlantAndEquipmentOtherAccumulatedDepreciation	507121	usd
CY2022Q1	us-gaap	Property Plant And Equipment Other Accumulated Depreciation PropertyPlantAndEquipmentOtherAccumulatedDepreciation	323461	usd
CY2023Q1	us-gaap	Property Plant And Equipment Other Net PropertyPlantAndEquipmentOtherNet	897735	usd
CY2022Q1	us-gaap	Property Plant And Equipment Other Net PropertyPlantAndEquipmentOtherNet	979297	usd
CY2023	us-gaap	Depreciation Depreciation	183660	usd
CY2022	us-gaap	Depreciation Depreciation	178924	usd
CY2023	us-gaap	Other Depreciation And Amortization OtherDepreciationAndAmortization	139689	usd
CY2022	us-gaap	Other Depreciation And Amortization OtherDepreciationAndAmortization	113000	usd
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Expiration Period SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod	P2040Y
CY2023	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	1000000	usd
CY2023	ntrb	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTax	On December 22, 2017, the Tax Cuts and Jobs Act (the “Tax Act”) significantly revised U.S. corporate income tax law by, among other things, reducing the corporate rate from 34% to 21%.
CY2022Q2	ntrb	Issuance Of Common Stock IssuanceOfCommonStock	33397	shares
CY2023Q1	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	2316748	usd
CY2022Q1	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	1612724	usd
CY2023	ntrb	Stock Issued For Services StockIssuedForServices	-1299882	usd
CY2022	ntrb	Stock Issued For Services StockIssuedForServices	-1131114	usd
CY2023	us-gaap	Asset Impairment Charges AssetImpairmentCharges	-1051714	usd
CY2022	us-gaap	Asset Impairment Charges AssetImpairmentCharges	-982976	usd
CY2023Q1	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	4668344	usd
CY2022Q1	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	3726814	usd
CY2020Q1	ntrb	Note Payables Description NotePayablesDescription	On March 21, 2020, the Coronavirus Aid Relief and Economic Security Act (“CARES ACT” was enacted. The CARES ACT established the Paycheck Protection Program (“PPP”) which funds small businesses through federally guaranteed loans. Under the PPP, companies are eligible for forgiveness of principal and interest if the proceeds are used for eligible payroll costs, rent and utility costs. On June 17, 2020, the Company’s subsidiary, 4P Therapeutics, was advanced $34,870 under the PPP, all of which was forgiven as of April 30, 2021. The Company recorded a gain on the extinguishment of debt of $34,870 during the year ended January 31, 2022.
CY2020Q3	us-gaap	Proceeds From Loan Originations1 ProceedsFromLoanOriginations1	100000	usd
CY2021Q4	us-gaap	Conversion Of Stock Shares Converted1 ConversionOfStockSharesConverted1	17182	shares
CY2023	us-gaap	Line Of Credit Facility Frequency Of Payment And Payment Terms LineOfCreditFacilityFrequencyOfPaymentAndPaymentTerms	Active Intelligence, the Company’s newly acquired subsidiary, entered into an agreement with the Carolina Small Business Development Fund for a line of credit of $160,000 due October 16, 2029, with interest of 5% per year.
CY2023Q1	us-gaap	Debt Default Longterm Debt Amount DebtDefaultLongtermDebtAmount	139184	usd
CY2023	us-gaap	Debt Instrument Periodic Payment Interest DebtInstrumentPeriodicPaymentInterest	1697	usd
CY2022	us-gaap	Line Of Credit Facility Periodic Payment Principal LineOfCreditFacilityPeriodicPaymentPrincipal	8344	usd
CY2023	ntrb	Gain On Extinguishment Of Debt GainOnExtinguishmentOfDebt	8344	usd
CY2023	us-gaap	Debt Instrument Periodic Payment Principal DebtInstrumentPeriodicPaymentPrincipal	13611	usd
CY2023	ntrb	Due Balance Amount DueBalanceAmount	100627	usd
CY2023Q1	us-gaap	Convertible Notes Payable Current ConvertibleNotesPayableCurrent	15344	usd
CY2022Q2	ntrb	Agreement Purchase Description AgreementPurchaseDescription	On April 3, 2022, the Company entered into a retail installment agreement for the purchase of an automobile. The contract price was $32,274, of which $22,794 was financed. The agreement is for five years bearing interest at 2.95% per annum with payments of $495 per month. The loan is secured by automobile. As of January 31, 2023, the amount due was $19,610 of which $4,396 is current.
CY2023	us-gaap	Debt Instrument Maturity Date Description DebtInstrumentMaturityDateDescription	The leases mature in 2025 and 2026.
CY2023	us-gaap	Subordinated Borrowing Interest Rate SubordinatedBorrowingInterestRate	0.05	pure
CY2022Q1	us-gaap	Loans And Leases Receivable Net Reported Amount LoansAndLeasesReceivableNetReportedAmount	121544	usd
CY2023	us-gaap	Other Expenses OtherExpenses	6289	usd
CY2022	us-gaap	Other Expenses OtherExpenses	118421	usd
CY2022Q3	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Expiration Period SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod	P3Y
CY2019Q2	ntrb	Common Stock Of Description CommonStockOfDescription	the Company effected a one-for-four reverse stock split, pursuant to which each share of common stock became converted into 0.25 shares of common stock, and the Company decreased its authorized common stock from 100,000,000 to 25,000,000 shares.
CY2022Q2	ntrb	Fair Value Of Compensation Expense FairValueOfCompensationExpense	113155	usd
CY2023Q1	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	1131500	usd
CY2022Q1	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	1181500	usd
CY2023Q1	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	351070	usd
CY2022Q1	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	254587	usd
CY2023Q1	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	780430	usd
CY2022Q1	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	926913	usd
CY2021Q1	ntrb	License Fee LicenseFee	50000	usd
CY2023	ntrb	Exercise Price ExercisePrice	7.5
CY2023Q1	ntrb	Termination Expense TerminationExpense	174025	usd
CY2023	us-gaap	Interest Expense Deposits InterestExpenseDeposits	33334	usd
CY2023	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	146483	usd
CY2022	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	129817	usd
CY2023Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	113109	usd
CY2023Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	113109	usd
CY2023Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	113109	usd
CY2023Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Five FiniteLivedIntangibleAssetsAmortizationExpenseYearFive	113109	usd
CY2023Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense After Year Five FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive	113109	usd
CY2023Q1	ntrb	Finite Lived Intangible Asset Amortization Expense After Year Five FiniteLivedIntangibleAssetAmortizationExpenseAfterYearFive	214885	usd
CY2023Q1	us-gaap	Other Intangible Assets Net OtherIntangibleAssetsNet	780430	usd
CY2022Q2	us-gaap	Allocated Share Based Compensation Expense Net Of Tax AllocatedShareBasedCompensationExpenseNetOfTax	53200	usd
CY2022Q3	us-gaap	Stock Issued During Period Shares Purchase Of Assets StockIssuedDuringPeriodSharesPurchaseOfAssets	137084	shares
CY2022Q3	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Expiration Period SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod	P3Y
CY2023	us-gaap	Related Party Transaction Amounts Of Transaction RelatedPartyTransactionAmountsOfTransaction	399075	usd
CY2022Q3	us-gaap	Stock Issued During Period Shares Purchase Of Assets StockIssuedDuringPeriodSharesPurchaseOfAssets	35000	shares
CY2022Q3	us-gaap	Sale Of Stock Price Per Share SaleOfStockPricePerShare	3.59
CY2022Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Expiration Period SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod	P5Y
CY2022Q4	us-gaap	Stock Issued During Period Shares Purchase Of Assets StockIssuedDuringPeriodSharesPurchaseOfAssets	107500	shares
CY2022	ntrb	Issuance Of Common Stock IssuanceOfCommonStock	25000	shares
CY2023	us-gaap	Option Indexed To Issuers Equity Shares OptionIndexedToIssuersEquityShares	10000	shares
CY2023Q1	us-gaap	Redeemable Noncontrolling Interest Equity Other Carrying Amount RedeemableNoncontrollingInterestEquityOtherCarryingAmount	32641	usd
CY2022Q3	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	296875	usd
CY2022Q3	ntrb	Issuance Of Common Stock IssuanceOfCommonStock	55417	shares
CY2022Q3	ntrb	Cancelled Shares CancelledShares	1400000	shares
CY2021Q1	us-gaap	Broadcasters License Agreement Commitments Description BroadcastersLicenseAgreementCommitmentsDescription	in connection with the Company’s License Agreement with Rambam, pursuant to a Stock Purchase Agreement with BPM Inno Ltd (“BPM”), the Company issued 94,962 shares of common stock to BPM and received proceeds of $700,000 to be applied to product development expenses under the License Agreement. The Company entered into the Stock Purchase Agreement with BPM in December 2020 and received a payment of $60,000 which is included in Stockholders’ Equity as Subscription Payable in the Company’s consolidated balance sheet as of January 31, 2021. In February 2021, BPM advanced a payment for the Company to Rambam in the amount of $57,000 for the license fee. The balance of the funds of $583,000 was received in February 2021. On February 15, 2021, the Company issued 14,583 shares of common stock, valued at $350,000, for consulting fees in connection with the Rambam License Agreement discussed in Note 10.
CY2021Q1	us-gaap	Common Stock Share Subscribed But Unissued Subscriptions Receivable CommonStockShareSubscribedButUnissuedSubscriptionsReceivable	10000	usd
CY2021	ntrb	Subcription Payable Shares SubcriptionPayableShares	1090	shares
CY2021Q4	ntrb	Common Stock Allotment Description CommonStockAllotmentDescription	the Company, having been approved for the listing of its common stock on The Nasdaq Capital Market effective October 1, 2021, consummated a public offering (the “IPO”) of units (the “Units”), of common stock and warrants that were offered in the IPO on The Nasdaq Capital Market, which included 1,232,000 (each a “Unit”), each Unit consisting of one share of common stock, par value $0.001 per share, and one warrant (each a “Warrant”) at a price of $5.36 per Unit. Each Warrant is immediate exercisable, will entitle the holder to purchase one share of common stock at an exercise price of $6.43 and will expire five (5) years from the date of issuance. The underwriters’ over-allotment option was exercised for 184,800 warrants to purchase shares of common stock bringing to total net proceeds to the Company from the IPO to $5,836,230. The shares of common stock and Warrants are separately transferred immediately upon issuance.
CY2021Q1	us-gaap	Excess Stock Shares Issued ExcessStockSharesIssued	457795	shares
CY2021Q1	us-gaap	Sale Of Stock Consideration Received On Transaction SaleOfStockConsiderationReceivedOnTransaction	2942970	usd
CY2021Q4	us-gaap	Extinguishment Of Debt Amount ExtinguishmentOfDebtAmount	100000	usd
CY2021Q4	us-gaap	Excess Stock Shares Issued ExcessStockSharesIssued	28749	shares
CY2021Q4	ntrb	Consulting Services ConsultingServices	144000	usd
CY2021Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	84233	shares
CY2021Q4	us-gaap	Shares Issued Price Per Share SharesIssuedPricePerShare	5.36
CY2021Q4	us-gaap	Assets Fair Value Adjustment AssetsFairValueAdjustment	196589	usd
CY2021Q4	ntrb	Cashless Warrants CashlessWarrants	42117	shares
CY2021Q4	us-gaap	Excess Stock Shares Issued ExcessStockSharesIssued	17381	shares
CY2021	us-gaap	Sale Of Stock Number Of Shares Issued In Transaction SaleOfStockNumberOfSharesIssuedInTransaction	32813	shares
CY2022Q1	us-gaap	Excess Stock Shares Issued ExcessStockSharesIssued	11667	shares
CY2023Q1	us-gaap	Shares Issued SharesIssued	25000	shares
CY2023	ntrb	Schedule Of Additional Relating Warrants Outstanding ScheduleOfAdditionalRelatingWarrantsOutstanding	<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td colspan="2" style="white-space: nowrap"><b> </b></td><td style="white-space: nowrap"><b> </b></td><td style="white-space: nowrap"><b> </b></td> <td colspan="2" style="white-space: nowrap"><b> </b></td><td style="white-space: nowrap"><b> </b></td><td style="white-space: nowrap"><b> </b></td> <td colspan="2" style="white-space: nowrap; text-align: center"><b>Weighted Average</b></td><td style="white-space: nowrap"><b> </b></td><td style="white-space: nowrap"><b> </b></td> <td colspan="2" style="white-space: nowrap; text-align: center"><b>Weighted Average</b></td><td style="white-space: nowrap"><b> </b></td><td style="white-space: nowrap"><b> </b></td> <td colspan="2" style="white-space: nowrap"><b> </b></td><td style="white-space: nowrap"><b> </b></td><td style="white-space: nowrap"><b> </b></td> <td colspan="2" style="white-space: nowrap; text-align: center"><b>Weighted Average</b></td><td style="white-space: nowrap"><b> </b></td><td style="white-space: nowrap"><b> </b></td> <td colspan="2" style="white-space: nowrap"><b> </b></td><td style="white-space: nowrap"><b> </b></td></tr> <tr style="vertical-align: bottom"> <td colspan="2" style="white-space: nowrap"><b>Range of Exercise</b></td><td style="white-space: nowrap"><b> </b></td><td style="white-space: nowrap"><b> </b></td> <td colspan="2" style="white-space: nowrap; text-align: center"><b>Number</b></td><td style="white-space: nowrap"><b> </b></td><td style="white-space: nowrap"><b> </b></td> <td colspan="2" style="white-space: nowrap; text-align: center"><b>Remaining Contractual</b></td><td style="white-space: nowrap"><b> </b></td><td style="white-space: nowrap"><b> </b></td> <td colspan="2" style="white-space: nowrap; text-align: center"><b>Exercise Price for</b></td><td style="white-space: nowrap"><b> </b></td><td style="white-space: nowrap"><b> </b></td> <td colspan="2" style="white-space: nowrap; text-align: center"><b>Number</b></td><td style="white-space: nowrap"><b> </b></td><td style="white-space: nowrap"><b> </b></td> <td colspan="2" style="white-space: nowrap; text-align: center"><b>Exercise Price for</b></td><td style="white-space: nowrap"><b> </b></td><td style="white-space: nowrap"><b> </b></td> <td colspan="2" style="white-space: nowrap; text-align: center"><b>Intrinsic</b></td><td style="white-space: nowrap"><b> </b></td></tr> <tr style="vertical-align: bottom"> <td colspan="2" style="white-space: nowrap; text-align: center; border-bottom: Black 1.5pt solid"><b>Prices</b></td><td style="white-space: nowrap; padding-bottom: 1.5pt"><b> </b></td><td style="white-space: nowrap; padding-bottom: 1.5pt"><b> </b></td> <td colspan="2" style="text-align: center; white-space: nowrap; border-bottom: Black 1.5pt solid"><b>Outstanding</b></td><td style="white-space: nowrap; padding-bottom: 1.5pt"><b> </b></td><td style="white-space: nowrap; padding-bottom: 1.5pt"><b> </b></td> <td colspan="2" style="white-space: nowrap; text-align: center; border-bottom: Black 1.5pt solid"><b>Life(Years)</b></td><td style="white-space: nowrap; padding-bottom: 1.5pt"><b> </b></td><td style="white-space: nowrap; padding-bottom: 1.5pt"><b> </b></td> <td colspan="2" style="white-space: nowrap; text-align: center; border-bottom: Black 1.5pt solid"><b>Shares Outstanding</b></td><td style="white-space: nowrap; padding-bottom: 1.5pt"><b> </b></td><td style="white-space: nowrap; padding-bottom: 1.5pt"><b> </b></td> <td colspan="2" style="white-space: nowrap; text-align: center; border-bottom: Black 1.5pt solid"><b>Exercisable</b></td><td style="white-space: nowrap; padding-bottom: 1.5pt"><b> </b></td><td style="white-space: nowrap; padding-bottom: 1.5pt"><b> </b></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; white-space: nowrap; text-align: center"><b>Shares Exercisable</b></td><td style="white-space: nowrap; padding-bottom: 1.5pt"><b> </b></td><td style="white-space: nowrap; padding-bottom: 1.5pt"><b> </b></td> <td colspan="2" style="white-space: nowrap; text-align: center; border-bottom: Black 1.5pt solid"><b>Value</b></td><td style="white-space: nowrap; padding-bottom: 1.5pt"><b> </b></td></tr> <tr style="vertical-align: bottom"> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">12.00</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 12%; text-align: right">54,633</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 12%; text-align: right">0.24</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">12.00</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 11%; text-align: right">54,633</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">12.00</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-143">-</div></td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">$</td><td style="text-align: right">6.43</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,082,205</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3.68</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">6.43</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,082,205</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">6.43</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-144">-</div></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">$</td><td style="text-align: right">4.20</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">145,833</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1.73</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">4.20</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">145,833</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">4.20</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">$</td><td style="text-align: right">7.50</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">25,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">4.77</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">7.50</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">25,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">7.50</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; background-color: white"> </p>
CY2021Q4	us-gaap	Shares Issued SharesIssued	408333	shares
CY2022Q1	ntrb	Additional Share AdditionalShare	233333	shares
CY2021Q4	ntrb	Common Stock Reserved CommonStockReserved	408333	shares
CY2023Q1	us-gaap	Investment Owned Balance Shares InvestmentOwnedBalanceShares	171331	shares
CY2023	ntrb	Purchase Shares PurchaseShares	279584	shares
CY2023	ntrb	Fair Value Options Service Amount FairValueOptionsServiceAmount	732130	usd
CY2022Q2	us-gaap	Shares Issued SharesIssued	190751	shares
CY2022Q2	us-gaap	Share Price SharePrice	4.58
CY2022Q2	ntrb	Risk Free Interest Rate RiskFreeInterestRate	5328.32	pure
CY2023Q1	us-gaap	Derivative Forward Interest Rate DerivativeForwardInterestRate	0	pure
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P1Y6M
CY2023Q1	us-gaap	Long Duration Contracts Assumptions By Product And Guarantee Volatility Rate LongDurationContractsAssumptionsByProductAndGuaranteeVolatilityRate	1.6269	pure
CY2023	ntrb	Risk Free Interest Rate RiskFreeInterestRate	0.0101	pure
CY2023	ntrb	Schedule Of Option Outstanding ScheduleOfOptionOutstanding	<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td colspan="2" style="white-space: nowrap"><b> </b></td><td style="white-space: nowrap"><b> </b></td><td style="white-space: nowrap"><b> </b></td> <td colspan="2" style="white-space: nowrap"><b> </b></td><td style="white-space: nowrap"><b> </b></td><td style="white-space: nowrap"><b> </b></td> <td colspan="2" style="white-space: nowrap; text-align: center"><b>Weighted Average</b></td><td style="white-space: nowrap"><b> </b></td><td style="white-space: nowrap"><b> </b></td> <td colspan="2" style="white-space: nowrap; text-align: center"><b>Weighted Average</b></td><td style="white-space: nowrap"><b> </b></td><td style="white-space: nowrap"><b> </b></td> <td colspan="2" style="white-space: nowrap"><b> </b></td><td style="white-space: nowrap"><b> </b></td><td style="white-space: nowrap"><b> </b></td> <td colspan="2" style="white-space: nowrap; text-align: center"><b>Weighted Average</b></td><td style="white-space: nowrap"><b> </b></td><td style="white-space: nowrap"><b> </b></td> <td colspan="2" style="white-space: nowrap"><b> </b></td><td style="white-space: nowrap"><b> </b></td></tr> <tr style="vertical-align: bottom"> <td colspan="2" style="text-align: center; white-space: nowrap"><b>Range of Exercise</b></td><td style="white-space: nowrap"><b> </b></td><td style="white-space: nowrap"><b> </b></td> <td colspan="2" style="white-space: nowrap; text-align: center"><b>Number</b></td><td style="white-space: nowrap"><b> </b></td><td style="white-space: nowrap"><b> </b></td> <td colspan="2" style="white-space: nowrap; text-align: center"><b>Remaining Contractual</b></td><td style="white-space: nowrap"><b> </b></td><td style="white-space: nowrap"><b> </b></td> <td colspan="2" style="white-space: nowrap; text-align: center"><b>Exercise Price for</b></td><td style="white-space: nowrap"><b> </b></td><td style="white-space: nowrap"><b> </b></td> <td colspan="2" style="white-space: nowrap; text-align: center"><b>Number</b></td><td style="white-space: nowrap"><b> </b></td><td style="white-space: nowrap"><b> </b></td> <td colspan="2" style="white-space: nowrap; text-align: center"><b>Exercise Price for</b></td><td style="white-space: nowrap"><b> </b></td><td style="white-space: nowrap"><b> </b></td> <td colspan="2" style="white-space: nowrap; text-align: center"><b>Intrinsic</b></td><td style="white-space: nowrap"><b> </b></td></tr> <tr style="vertical-align: bottom"> <td colspan="2" style="white-space: nowrap; text-align: center; border-bottom: Black 1.5pt solid"><b>Prices</b></td><td style="white-space: nowrap; padding-bottom: 1.5pt"><b> </b></td><td style="white-space: nowrap; padding-bottom: 1.5pt"><b> </b></td> <td colspan="2" style="text-align: center; white-space: nowrap; border-bottom: Black 1.5pt solid"><b>Outstanding</b></td><td style="white-space: nowrap; padding-bottom: 1.5pt"><b> </b></td><td style="white-space: nowrap; padding-bottom: 1.5pt"><b> </b></td> <td colspan="2" style="white-space: nowrap; text-align: center; border-bottom: Black 1.5pt solid"><b>Life(Years)</b></td><td style="white-space: nowrap; padding-bottom: 1.5pt"><b> </b></td><td style="white-space: nowrap; padding-bottom: 1.5pt"><b> </b></td> <td colspan="2" style="white-space: nowrap; text-align: center; border-bottom: Black 1.5pt solid"><b>Shares Outstanding</b></td><td style="white-space: nowrap; padding-bottom: 1.5pt"><b> </b></td><td style="white-space: nowrap; padding-bottom: 1.5pt"><b> </b></td> <td colspan="2" style="white-space: nowrap; text-align: center; border-bottom: Black 1.5pt solid"><b>Exercisable</b></td><td style="white-space: nowrap; padding-bottom: 1.5pt"><b> </b></td><td style="white-space: nowrap; padding-bottom: 1.5pt"><b> </b></td> <td colspan="2" style="white-space: nowrap; text-align: center; border-bottom: Black 1.5pt solid"><b>Shares Exercisable</b></td><td style="white-space: nowrap; padding-bottom: 1.5pt"><b> </b></td><td style="white-space: nowrap; padding-bottom: 1.5pt"><b> </b></td> <td colspan="2" style="white-space: nowrap; text-align: center; border-bottom: Black 1.5pt solid"><b>Value</b></td><td style="white-space: nowrap; padding-bottom: 1.5pt"><b> </b></td></tr> <tr style="vertical-align: bottom"> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">4.58</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 12%; text-align: right">46,666</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 12%; text-align: right">2.48</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">4.58</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 11%; text-align: right">46,666</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">4.58</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-168">-</div></td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">$</td><td style="text-align: right">4.16</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">144,085</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1.97</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">4.16</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">144,085</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">4.16</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-169">-</div></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">$</td><td style="text-align: right">4.50</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">58,334</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1.97</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">4.50</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">58,334</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">4.50</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-170">-</div></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">$</td><td style="text-align: right">4.09</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">78,750</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2.50</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">4.09</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">78,750</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">4.09</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-171">-</div></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">$</td><td style="text-align: right">3.59</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">35,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2.50</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">3.59</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">35,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">3.59</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">2,100</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">$</td><td style="text-align: right">3.75</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">57,500</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2.85</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">3.75</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">57,500</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">3.75</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-172">-</div></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">$</td><td style="text-align: right">4.12</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">50,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2.85</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">4.12</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">50,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">4.12</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-173">-</div></td><td style="text-align: left"> </td></tr> </table>
CY2023	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	1785597	usd
CY2022	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	1179620	usd
CY2023	us-gaap	Cost Depletion CostDepletion	294102	usd
CY2022	us-gaap	Cost Depletion CostDepletion	242534	usd
CY2023	us-gaap	Cost Depreciation Amortization And Depletion CostDepreciationAmortizationAndDepletion	2079699	usd
CY2022	us-gaap	Cost Depreciation Amortization And Depletion CostDepreciationAmortizationAndDepletion	1422154	usd
CY2023	ntrb	Pocono Pharmaceuticals PoconoPharmaceuticals	726702	usd
CY2022	ntrb	Pocono Pharmaceuticals PoconoPharmaceuticals	595087	usd
CY2023	ntrb	Therapeutics Therapeutics	23702	usd
CY2022	ntrb	Therapeutics Therapeutics	-40777	usd
CY2023	us-gaap	Gross Profit GrossProfit	750404	usd
CY2022	us-gaap	Gross Profit GrossProfit	554310	usd
CY2023	us-gaap	Other General And Administrative Expense OtherGeneralAndAdministrativeExpense	577930	usd
CY2022	us-gaap	Other General And Administrative Expense OtherGeneralAndAdministrativeExpense	556204	usd
CY2023	us-gaap	Other Selling General And Administrative Expense OtherSellingGeneralAndAdministrativeExpense	103181	usd
CY2022	us-gaap	Other Selling General And Administrative Expense OtherSellingGeneralAndAdministrativeExpense	96079	usd
CY2023	ntrb	Corporate Overheads CorporateOverheads	3234930	usd
CY2022	ntrb	Corporate Overheads CorporateOverheads	3370541	usd
CY2023	us-gaap	Other Research And Development Expense OtherResearchAndDevelopmentExpense	982227	usd
CY2022	us-gaap	Other Research And Development Expense OtherResearchAndDevelopmentExpense	411383	usd
CY2023	us-gaap	Goodwill Impairment Loss Net Of Tax GoodwillImpairmentLossNetOfTax	327326	usd
CY2022	us-gaap	Goodwill Impairment Loss Net Of Tax GoodwillImpairmentLossNetOfTax	2180836	usd
CY2023	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	5225594	usd
CY2022	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	6615043	usd
CY2023	us-gaap	Cost Of Goods And Services Sold Depreciation CostOfGoodsAndServicesSoldDepreciation	264156	usd
CY2022	us-gaap	Cost Of Goods And Services Sold Depreciation CostOfGoodsAndServicesSoldDepreciation	220524	usd
CY2023	us-gaap	Cost Of Goods And Services Sold Amortization CostOfGoodsAndServicesSoldAmortization	65987	usd
CY2022	us-gaap	Cost Of Goods And Services Sold Amortization CostOfGoodsAndServicesSoldAmortization	88217	usd
CY2023	us-gaap	Cost Of Goods And Services Sold Depreciation And Amortization CostOfGoodsAndServicesSoldDepreciationAndAmortization	330143	usd
CY2022	us-gaap	Cost Of Goods And Services Sold Depreciation And Amortization CostOfGoodsAndServicesSoldDepreciationAndAmortization	308741	usd
CY2023Q1	ntrb	Net Sales NetSales	2079699	usd
CY2022Q1	ntrb	Net Sales NetSales	1422154	usd
CY2023Q1	us-gaap	Property Plant And Equipment Owned Accumulated Depreciation PropertyPlantAndEquipmentOwnedAccumulatedDepreciation	897735	usd
CY2022Q1	us-gaap	Property Plant And Equipment Owned Accumulated Depreciation PropertyPlantAndEquipmentOwnedAccumulatedDepreciation	979297	usd
CY2023Q1	us-gaap	Other Assets OtherAssets	9456377	usd
CY2022Q1	us-gaap	Other Assets OtherAssets	12739660	usd
CY2023	us-gaap	Stock Issued During Period Shares Acquisitions StockIssuedDuringPeriodSharesAcquisitions	1400000	shares
CY2022Q3	us-gaap	Stockholders Equity Reverse Stock Split StockholdersEquityReverseStockSplit	adjusted for the 1-for-4 reverse stock split effective June 23, 2019 and the 7-for-6 forward stock split effective August 15, 2022
CY2023	us-gaap	Debt Instrument Maturity Date DebtInstrumentMaturityDate	2025-01-31
CY2023	ntrb	Percentage Of Net Income PercentageOfNetIncome	0.035	pure
CY2022Q3	ntrb	Agreed To Annual Salary AgreedToAnnualSalary	150000	usd
CY2020Q4	ntrb	Payment For Initial License Fee PaymentForInitialLicenseFee	50000	usd
CY2021Q1	ntrb	Payment For Initial License Fee PaymentForInitialLicenseFee	50000	usd
CY2023	us-gaap	Other Commitments Description OtherCommitmentsDescription	The Company had entered into a prior agreement, dated November 13, 2020, with BPM Inno Ltd., Kiryat, Israel (“BPM”), that, in consideration of BPM’s introduction of Rambam to the Company, provided for BPM to have the rights as the exclusive of agent of the Company with Rambam and any other parties similarly introduced by BPM, and for a commission payable to BPM by the Company of 4.5% of revenues received by the Company resulting from the introduction of Rambam (and any other companies as to which the exclusive agency of BPM was in effect), and for BPM’s payment of a royalty to Rambam. If the Company fails to commercialize the medical products subject to the License Agreement with Rambam within 36 months, under the November 13, 2020 agreement, BPM and the Company would share 50/50 in the revenues generated from sales of the licensed products from Rambam. This agreement further provides that it will be effective for a period of 10 years, with either party having the right to terminate on notice given 30 days prior to the desired termination, and also provided for certain territorial distribution rights of BPM as are set forth in the March 10, 2021 Distribution Agreement between the Company and BPM.
CY2023Q1	ntrb	Payments For Repurchase Of Warrant PaymentsForRepurchaseOfWarrant	25000	shares
CY2023Q1	us-gaap	Sale Of Stock Price Per Share SaleOfStockPricePerShare	7.5
CY2023	ntrb	Selling And Administrative Expenses SellingAndAdministrativeExpenses	175000	usd
CY2023Q1	us-gaap	Prepaid Taxes PrepaidTaxes	737654	usd
CY2023Q1	us-gaap	Deposits Deposits	250000	usd
CY2022Q1	ntrb	Warehouse Space WarehouseSpace	12000	pure
CY2022	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit		usd
CY2022Q1	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	3000	usd
CY2022Q1	us-gaap	Debt Instrument Maturity Date DebtInstrumentMaturityDate	2025-01-31
CY2022Q1	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P3Y
CY2022Q1	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	94134	usd
CY2022Q3	us-gaap	Notes Issued1 NotesIssued1	20000	usd
CY2023	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt		usd
CY2023	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet		usd
CY2023	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent		usd
CY2023	us-gaap	Stock Issued During Period Value Conversion Of Units StockIssuedDuringPeriodValueConversionOfUnits		usd
CY2022	ntrb	Stock Issued During Period Cashless Exercise Of Warrants StockIssuedDuringPeriodCashlessExerciseOfWarrants		usd
CY2023	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium		usd
CY2023	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt		usd
CY2022	ntrb	Treasury Stock Issued For Services TreasuryStockIssuedForServices		usd
CY2023	ntrb	Common Stock Issued For Service CommonStockIssuedForService		usd
CY2023	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock		usd
CY2023	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering		usd
CY2023	us-gaap	Repayments Of Related Party Debt RepaymentsOfRelatedPartyDebt		usd
CY2023	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments		usd
CY2023	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents		usd
CY2022	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents		usd
CY2023	us-gaap	Income Taxes Paid IncomeTaxesPaid		usd
CY2022	us-gaap	Income Taxes Paid IncomeTaxesPaid		usd
CY2022	ntrb	Common Stock Returned In Settlement CommonStockReturnedInSettlement		usd
CY2023	ntrb	Common Stock Issued For Settlement Of Notes Payable CommonStockIssuedForSettlementOfNotesPayable		usd
CY2023	ntrb	Common Stock Issued For Prepaid Consulting CommonStockIssuedForPrepaidConsulting		usd
CY2023	ntrb	Noncash Payment For License Agreement NoncashPaymentForLicenseAgreement		usd
CY2023	ntrb	Common Stock Issued For Subscription Payable CommonStockIssuedForSubscriptionPayable		usd
CY2022	ntrb	Promissory Note On Equipment Purchase PromissoryNoteOnEquipmentPurchase		usd
CY2023	ntrb	Settlement Of Liabilities For Common Stock SettlementOfLiabilitiesForCommonStock		usd
CY2023	us-gaap	Noncash Or Part Noncash Acquisition Net Nonmonetary Assets Acquired Liabilities Assumed1 NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1		usd
CY2023	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit		usd
CY2022	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit		usd
CY2023	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit		usd
CY2023	dei	Amendment Flag AmendmentFlag	false
CY2023	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2023	dei	Entity Central Index Key EntityCentralIndexKey	0001676047

Files In Submission

Name	View Source	Status
0001213900-23-032682-index-headers.html	Edgar Link	pending
0001213900-23-032682-index.html	Edgar Link	pending
0001213900-23-032682.txt	Edgar Link	pending
0001213900-23-032682-xbrl.zip	Edgar Link	pending
f10k2023ex31-1_nutriband.htm	Edgar Link	pending
f10k2023ex31-2_nutriband.htm	Edgar Link	pending
f10k2023ex32-1_nutriband.htm	Edgar Link	pending
f10k2023_nutriband.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
ntrb-20230131.xsd	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
ntrb-20230131_cal.xml	Edgar Link	unprocessable
ntrb-20230131_def.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
ntrb-20230131_lab.xml	Edgar Link	unprocessable
ntrb-20230131_pre.xml	Edgar Link	unprocessable
f10k2023_nutriband_htm.xml	Edgar Link	completed
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$NTRB
NutriBand Inc. Stock $ntrb

2023 Q2 Form 10-K Financial Statement

#000121390023032682 Filed on April 26, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$NTRB NutriBand Inc. Stock $ntrb

2023 Q2 Form 10-K Financial Statement

#000121390023032682 Filed on April 26, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$NTRB
NutriBand Inc. Stock $ntrb